GENZ Biotechnology
Streamlined Rapid Antibody Detection and Diagnostic Solutions

The spread of the COVID-19 virus has become a global healthcare issue across the world. The pandemic has compelled the healthcare industry to rapidly develop highly reliable diagnostic methods. The use of emerging scientific technologies can significantly improve detection and decision making. Rapid and precise molecular diagnostic technologies are crucial for screening, isolation, treatment, prevention and control of COVID-19. With Genzbio, the rapid detection and diagnosis of infected patients have been made easier with the help of virus-specific molecular tests. In addition, the organisation streamlines the process of identifying recovered patients using immunochromatographic rapid tests.. Besides, the availability of anti SARS-CoV-2 antibodies immunoassays and many other rapid antibody detection tests based on immunochromatographic techniques has been recently commercialized in the healthcare industry.Genzbio stepped into the medical sector with innovative, competitive, quality products such as COVID-19 testing kits, point of care testing system (Genzpro) s, COVID-19 antibody IgG testing eliza (GNZ), blood compatibility RH test (GNZ), and BRCA cancer testing (GNZ).

This London-based biotechnology startup is working on developing novel diagnostic testing solutions from in-vitro diagnostics to therapeutics. The company not only develops SARS-CoV-2 specific diagnostic rapid tests, virus-specific anti-human antibody rapid tests, and a standardized screening device, but also aims to deliver a consistent stream of innovative, affordable, and accessible diagnostic solutions.

Genzbio delivers a seamless experience for patients through its innovative, next-gen point of care diagnostic system. This involves a combination of a small, compact device, Genzpro, and an advanced low-cost test chip. The device is portable, easy-to-use, reliable for testing, and prevents the spread of SARS-CoV-2. The device reads the antigen/antibody quantity using Genzpro test chips in 7 minutes from the patients’ blood and nasal swab specimen. The test results get automatically stored in the Genzpro device and can be easily sent to the patient or doctor via email. Genzpro SARS-CoV-2 antibody test and Genzpro point of care (POC) immunoassay analyzer are the two solutions that the firm offers to conduct antibody rapid tests. Genzpro SARS-CoV-2 antibody tests are conducted for the detection of COVID-19 antibodies in the human blood that indicates recent or prior infection.

The gender of a newborn may be both overwhelming and at the same time critical to discover gender-related genetic disorders in infants. In order to do that, Genbio offers a product, GNZ, that can detect the gender of the baby three weeks prior to the birth and with higher accuracy than ultrasound at the 14th week. At Genz, breast cancer is one of their main focus areas, which led to the development of the GNZ-BRC test. Testing with GNZ-BRC determines gaining a mutation risk linked to breast cancer and demonstrates a life-long risk of diagnosis of breast cancer and how to prevent it. It differs from standard screening as it includes AI software and custom panels.

The pandemic has accelerated the development of technological breakthroughs and companies like Genzbio are leveraging the current trends in the healthcare industry to optimize patients’ lives. Genzbio’s aim of making a significant difference in people’s lives and addressing the world’s most important health concerns, backed by their innovative solutions, has yielded significant results among patients.